Table 1.
Baseline characteristics among GLP1-RA cohort and non-GLP1 RA cohort before and after propensity score matching.
| Before matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| GLP1-RA | Non-GLP1 RA | SMD | GLP1 RA | Non-GLP1 RA | SMD | |
| N | 162,257 | 9,103,212 | 162,253 | 162,253 | ||
| Age at Index | 52.4 ± 13.5 | 49.3 ± 17.0 | 0.2033 | 52.4 ± 13.5 | 52.5 ± 13.5 | 0.0058 |
| Sex | ||||||
| Female | 90,205(55.6%) | 4,956,607(54.4%) | 0.0230 | 90,205(55.6%) | 90,225(55.6%) | 0.0002 |
| Male | 52,864(32.6%) | 3,682,542(40.5%) | 0.1641 | 52,864(32.6%) | 53,069(32.7%) | 0.0027 |
| Race | ||||||
| White | 98,983(61.0%) | 5,640,368(62.0%) | 0.0197 | 98,983(61.0%) | 94,210(58.1%) | 0.0600 |
| Black or African American | 22,444(13.8%) | 1,542,116(16.9%) | 0.0862 | 22,444(13.8%) | 22,495(13.9%) | 0.0009 |
| Asian | 3985(2.5%) | 177,188(1.9%) | 0.0347 | 3985(2.5%) | 3678(2.3%) | 0.0125 |
| Socioeconomic factors | ||||||
| Problems related to housing and economic circumstances | 787(0.5%) | 22,674(0.2%) | 0.0390 | 787(0.5%) | 468(0.3%) | 0.0317 |
| Comorbidities | ||||||
| Hypertensive diseases | 82,878(51.1%) | 2,095,745(23.0%) | 0.6071 | 82,874(51.1%) | 83,011(51.2%) | 0.0017 |
| Type 2 diabetes mellitus | 81,091(50.0%) | 952,518(10.5%) | 0.9532 | 81,087(50.0%) | 81,364(50.1%) | 0.0034 |
| Chronic lower respiratory diseases | 16,243(10.0%) | 595,329(6.5%) | 0.1262 | 16,243(10.0%) | 15,368(9.5%) | 0.0182 |
| Ischemic heart diseases | 14,183(8.7%) | 490,656(5.4%) | 0.1311 | 14,183(8.7%) | 15,823(9.8%) | 0.0349 |
| Chronic kidney disease | 9897(6.1%) | 283,877(3.1%) | 0.1425 | 9897(6.1%) | 10,749(6.6%) | 0.0215 |
| Cerebrovascular diseases | 3859(2.4%) | 196,401(2.2%) | 0.0148 | 3859(2.4%) | 5647(3.5%) | 0.0654 |
| Neoplasms | 17,456(10.8%) | 776,252(8.5%) | 0.0756 | 17,456(10.8%) | 15,347(9.5%) | 0.0431 |
| Psychoactive substance use | 8470(5.2%) | 584,387(6.4%) | 0.0512 | 8470(5.2%) | 8543(5.3%) | 0.0020 |